Dr. Oliver Press is the Acting Director of Fred Hutch's Clinical Research Division. He is also Acting Senior Vice President and the Dr. Penny E. Petersen Memorial Chair of Lymphoma Research. At the University of Washington he is a Professor of Medicine and Adjunct Professor of Bioengineering.
Dr. Press received his Ph.D. and M.D. from the University of Washington and his B.S. in Biology from Stanford.
As the head of Clinical Research Division, Press is deeply involved in laboratory research, clinical research, patient care and mentorship.
In his own work, Press's has been at the forefront of developing new and novel therapies—particularly approaches that harness the immune system, known as immunotherapy—for blood cancers like leukemia, multiple myeloma, and especially lymphoma. He is particularly involved in a successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and has trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.
Dr. Press is the co-chair of the National Cancer Institute’s Lymphoma Steering Committee, helping to select the most promising new approaches in lymphoma treatment for testing in national phase 3 clinical trials. He is also co-chair of the University of Washington Nanotechnology Training Program and co-director of the Center for Intracellular Delivery of Biologics. Through these interdisciplinary collaborations, Dr. Press can leverage his experience with targeted cancer therapies to aid in the development of the next generation of medical breakthroughs.